Rubraca (Rucaparib Camsylate) Patent Expiration, LOE Window & CMS Spending
Rubraca (Rucaparib Camsylate) by Pharmaand Gmbh: FDA Orange Book core substance LOE 2031-02-10 (last listed 2035-08-17), 0 AB generics, $34.8M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pharmaand Gmbh |
| FDA Application & Pathway | N209115 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-02-10 |
| Last Listed Patent or Exclusivity Date | 2035-08-17 |
| Orange Book Patents (*PED Extensions) | 9 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $34.8M |
| 2024 Medicare Part D Spend | $31.5M |
| 2024 Medicaid Spend | $3.3M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |